The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Elevated PGC-1α Activity Sustains Mitochondrial Biogenesis and Muscle Function without Extending Survival in a Mouse Model of Inherited ALS
Open accessAbstract
SUMMARY The transcriptional coactivator PGC-1α induces multiple effects on muscle, including increased mitochondrial mass and activity. Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, adult-onset neurodegenerative disorder characterized by selective loss of motor neurons and skeletal muscle degeneration. An early event is thought to be denervation-induced muscle atrophy accompanied by alterations in mitochondrial activity and morphology within muscle. We now report that elevation of PGC-1α levels in muscles of mice that develop fatal paralysis from an ALS-causing SOD1 mutant elevates PGC-1α-dependent pathways throughout disease course. Mitochondrial biogenesis and activity are maintained through end-stage disease, accompanied by retention of muscle function, delayed muscle atrophy, and significantly improved muscle endurance even at late disease stages. However, survival was not extended. Therefore, muscle is not a primary target of mutant SOD1-mediated toxicity, but drugs increasing PGC-1α activity in muscle represent an attractive therapy for maintaining muscle function during progression of ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546
Self-citationMetabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 1×
“Forced expression of PGC-1a in cultured mammalian cells or specific tissues of transgenic mice increases number and mass of mitochondria together with a strong enhancement of cellular respiratory capacity (Lin et al., 2005).”
Self-citationOnset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Self-citationHIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054 · cited 1×
“, 2007), and induces angiogenesis (Arany et al., 2008).”
Self-citationNon–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008
Self-citationSandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974 · cited 3×
“PGC-1a was previously shown (Sandri et al., 2006) to inhibit expression of genes involved in muscle degeneration (including those encoding the ubiquitin ligase MuRF-1 and”
InfluentialSelf-citationLi, Q., Vande Velde, C., Israelson, A., Xie, J., Bailey, A. O., Dong, M.-Q., Chun, S.-J., Roy, T., Winer, L., Yates, J. R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014862107 · Cited by 169
Self-citation
Cited by
Mitochondrial Dysfunction in Neurodegenerative Diseases
Johri, A., & Beal, M. F. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192138 · Cited by 806
Austin, S., & St-Pierre, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.113662 · Cited by 608
Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment
Golpich, M., Amini, E., Mohamed, Z., Azman Ali, R., Mohamed Ibrahim, N., & Ahmadiani, A. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12655 · Cited by 532
Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease
Tracey, T. J., Steyn, F. J., Wolvetang, E. J., & Ngo, S. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00010 · Cited by 433
Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise
Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galán-Díez, M., Lacampagne, A., Mitchell, S. J., Mattison, J. A., Chen, Y., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.004 · Cited by 426
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Villena, J. A. (2015) · The FEBS Journal · doi:10.1111/febs.13175 · Cited by 405
Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis
Nijssen, J., Comley, L. H., & Hedlund, E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1708-8 · Cited by 339
Qian, L., Zhu, Y., Deng, C., Liang, Z., Chen, J., Chen, Y., Wang, X., Liu, Y., Tian, Y., & Yang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01756-w · Cited by 338
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
“In a mouse model of ALS, activation of PGC1α has promoted several beneficial effects on muscle (Da Cruz et al., 2012a, 2012b; Nijssen, Comley, & Hedlund, 2017).”
BackgroundTurn up the power - pharmacological activation of mitochondrial biogenesis in mouse models
Komen, J. C., & Thorburn, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12413 · Cited by 149
“Still, the improvement in muscle function in the mice did show that targeting peripheral activation of PGC-1α may improve quality of life in ALS patients (Da Cruz et al., 2012).”
BackgroundNeuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis
Tesla, R., Wolf, H. P., Xu, P., Drawbridge, J., Estill, S. J., Huntington, P., McDaniel, L., Knobbe, W., Burket, A., Tran, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213960109 · Cited by 129
Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis
Cappello, V., & Francolini, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102092 · Cited by 119
Thau, N., Knippenberg, S., Körner, S., Rath, K. J., Dengler, R., & Petri, S. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318275df4b · Cited by 97
PGC-1 is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis
Eschbach, J., Schwalenstocker, B., Soyal, S. M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.-C., Birve, A., Meyer, T., Dupuis, L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt202 · Cited by 75
Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis
Jiang, Z., Wang, W., Perry, G., Zhu, X., & Wang, X. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0037-x · Cited by 66
“Finally, overexpression of the key biogenesis regulator PGC-1α could also alleviate ALS symptoms in SOD1 G37R transgenic mice [82].”
Background
Metadata
- Authors
- Da Cruz, S., Parone, P. A., Lopes, V. S., Lillo, C., McAlonis-Downes, M., Lee, S. K., Vetto, A. P., Petrosyan, S., Marsala, M., Murphy, A. N., Williams, D. S., Spiegelman, B. M., & Cleveland, D. W.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 15
- Issue
- 5
- Pages
- 778-786
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2102301706
- Cited by
- 177
- References
- 7
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.